Rapport Therapeutics Inc

Insider sales by Rapport Therapeutics’ CEO show disciplined rebalancing, but option purchases signal confidence in the company’s pipeline and future growth prospects.

Insider buying of 120k options signals confidence in the company’s CNS drug RAP‑219; read how leadership’s stake and early payer deals could shape future value.

Rapport Therapeutics’ insider buying shows confidence in RAP‑219, a CNS‑targeted pain drug, as Phase IIb trials aim for FDA‑approved relief with minimal side effects.

Insider sale of 8,500 RAPP shares by CSO Bredt David shows disciplined liquidity management, not panic—watch Phase 3 results for potential upside.